Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold -- Ignore unavailable to you. Want to Upgrade?

To: Sir Auric Goldfinger who wrote (4189)	1/2/2003 4:24:52 PM
From: StockDung	Respond to of 5582

WHY USE CLARITIN WHEN YOU HAVE GUMM AND QUIGLEY? LOL Wyeth wins OK for Claritin copycat, J&J bows out Friday December 20, 4:12 pm ET NEW YORK, Dec 20 (Reuters) - Wyeth (NYSE:WYE - News) on Friday said U.S. regulators had approved its rival over-the-counter version of Schering-Plough's allergy drug Claritin and that it will begin shipping the less-expensive product next week. ADVERTISEMENT Later in the day, Johnson & Johnson (NYSE:JNJ - News) acknowledged it had nixed earlier plans to sell its own non-prescription form of Claritin -- leaving Claritin and Alavert to fight it out among themselves on drugstore shelves. Madison, New Jersey-based Wyeth said the U. S. Food and Drug Administration had cleared Alavert, its 10-milligram tablet that quickly dissolves on the tongue. It is a copycat of Schering-Plough's non-prescription RediTabs, which can retail for almost $1 per tablet in drugstores. Wyeth said in a release the suggested retail price for a package of 48 Alavert tablets is about $27, or about 57 cents per tablet. Schering-Plough, which has lost its U.S. marketing exclusivity on Claritin, began selling it without a prescription in U.S. stores on December 10. Its five formulations sell for between 90 cents and $1.35 per tablet, a steep discount from its former cost of up to $2.75 per tablet as a prescription drug. "We have no plans to launch loratadine at this time," a J&J spokesman told Reuters, referring to the chemical name of Claritin. "But as for as the future, we can't comment on our plans," the spokesman added. Johnson & Johnson, whose aggressive consumer products division sells Tylenol painkiller, declined to explain why it had changed course from its earlier plans to challenge Claritin. "We've decided to concentrate our attention on Tylenol allergy, flu and sinus products," the J&J spokesman said, declining further comment. Claritin garnered annual sales of over $3 billion in 2001 as a prescription drug, thanks to huge advertising campaigns and the fact it does not cause drowsiness seen with older allergy treatments. Claritin and Alavert will compete not only with each other, but also against two far-costlier prescription treatments -- Aventis SA's (NYSE:AVE - News) non-sedating Allegra and Pfizer Inc.s (NYSE:PFE - News) Zyrtec, which causes sleepiness in a fair number of patients.

To: Sir Auric Goldfinger who wrote (4189)	1/5/2003 2:40:26 PM
From: StockDung	Respond to of 5582

"You take a swoller of this 3 or 4 times a day and in a week or ten days your cold will be gone." ...Granny The Beverly Hillbillies

To: Sir Auric Goldfinger who wrote (4189)	2/25/2003 2:30:41 PM
From: StockDung	Respond to of 5582

GUMM WARS->The Quigley Corporation Introduces COLD-EEZE Nasal Spray; Contains Zinc Gluconate To Treat Common Cold and Aloe Vera to Soothe Nasal Passages - BusinessWire DOYLESTOWN, Pa., Feb 25, 2003 (BUSINESS WIRE) -- The Quigley Corporation originator of the zinc cold product category, announced today the launch of a new offering in its COLD-EEZE line of remedies. The product, a moisturizing nasal spray containing the active ingredient Zinc Gluconate and also containing Aloe Vera gel, will begin shipping to retail in July. The new COLD-EEZE Nasal Spray is designed to effectively reduce the duration of symptoms of the common cold. Its 0.68 mg of Zinc Gluconate per dose penetrates nasal, sinus and throat cavities to deliver the zinc ions where they are needed most. Additionally, the spray contains Aloe Vera gel to help soothe nasal passages that are dry and inflamed. The formula is non-habit forming and will not interact with other medicines. "The COLD-EEZE Nasal Spray, manufactured under U.S. patent # 5,622,724, leverages our strong equity in cold care and broadens our portfolio of zinc cold remedies," said Guy Quigley, president and CEO of the Quigley Corporation. "Along with the proven efficacy of our lozenges and gum, the new Nasal Spray complements our existing COLD-EEZE line while offering consumers a new alternative in their fight to get better faster." The COLD-EEZE Nasal Spray will be sold in a dynamic package that allows consumers to recognize the product as part of the COLD-EEZE line. The launch of the Nasal Spray will be supported with an integrated marketing campaign, including advertising, public relations and in-store support. Study Shows: Treat it with the COLD-EEZE Lozenges In a retrospective study conducted over three years at the Heritage School facility in Provo, Utah, 378 adolescents ranging in age from 12 to 18 were given COLD-EEZE both prophylactically and symptomatically for more than 170,000 patient days. The study found that COLD-EEZE, when taken daily, statistically lessened the number of colds study participants suffered per year by over 50%. The colds that did develop lasted for an average period of 6 days when treated with COLD-EEZE and 10 days when not. The study also found that the use of COLD-EEZE to treat a cold statistically reduced antibiotic use for respiratory illnesses by 92%. In a double-blind, placebo-controlled study conducted at the Cleveland Clinic and published in the Annals of Internal Medicine, those patients taking COLD-EEZE recovered completely from their colds more than three days faster (on average) than the patients who received a placebo. In addition, individual symptoms went away faster. On average, the COLD-EEZE group had 2.5 fewer days of coughing, 1 less day of headache, 1 less day of hoarseness, 2 fewer days of nasal congestion, 3 fewer days of nasal drainage and 2 fewer days of sore throat. About The Quigley Corporation The Quigley Corporation is a leading developer and marketer of diversified health products including the COLD-EEZE family of patented Zinc Gluconate Glycine (ZIGG) lozenges, gums and sugar free tablets. In addition to Over-The-Counter (OTC) products, the Company has formed Quigley Pharma Inc. (http://www.QuigleyPharma.com), a wholly owned ethical pharmaceutical subsidiary, to introduce a line of patented prescription drugs. The Quigley Corporation's customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. Additional information about The Quigley Corporation is available on its Web site at www.quigleyco.com. Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition. G.S. Schwartz & Co. Alissa Pinck, 212/725-4500 (media) apinck@schwartz.com or The Investor Relations Group Lisa Lindberg, 212/825-3210 (Investors) theproteam@aol.com businesswire.com Today's News On The Net - Business Wire's full file on the Internet with Hyperlinks to your home page. Copyright (C) 2003 Business Wire. All rights reserved.